ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing
17 8월 2023 - 9:00PM
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the
dental and spine markets, today announced it has expanded its
cooperation agreement with Brainlab, an innovation leader with an
expansive and diversified spine imaging, planning, and navigation
portfolio, as well as robotic imaging, surgical assistance, and
mixed reality to support spinal surgeries.
ZimVie and Brainlab have started a joint project to achieve
compatibility between ZimVie’s Vital and Virage fixation systems
and Brainlab spine and trauma navigation technologies, which help
surgeons plan and execute spinal procedures, accurately place
pedicle screws, and minimize radiation exposure. In addition,
ZimVie will co-market the Brainlab spine and trauma navigation
technologies alongside its existing spine implant solutions
globally.
“We are excited to partner with Brainlab to bring into the
operating room differentiated technology aiming at enhancing
workflow and accuracy for surgeons and staff,” said Vafa Jamali,
President and Chief Executive Officer of ZimVie. “We have been
focused on expanding our portfolio with enabling technology to
drive greater adoption across our spine portfolio. Our common
interest in delivering clinical and economic value to our customers
and patients aligns perfectly with ZimVie’s strategic
initiatives.”
“As the provider of an advanced portfolio of spine enabling
technologies in the market, Brainlab is an ideal partner in our
mission to make spine surgery more efficient and reproducible
without compromising accuracy and safety,” said Rebecca Whitney,
President of Global Spine at ZimVie. “Additionally, we will benefit
from a complementary customer base with little overlap in existing
accounts. The introduction of the Brainlab portfolio of enabling
technologies to ZimVie surgeon customers represents potential
upside for both companies and helps us to make an impact on the
lives of physicians and patients.”
For more information on ZimVie Spine solutions for restorative
procedures, please visit https://www.zimvie.com/en/spine.html.
About ZimVieZimVie is a global life sciences
leader in the dental and spine markets that develops, manufactures,
and delivers a comprehensive portfolio of products and solutions
designed to treat a wide range of spine pathologies and support
dental tooth replacement and restoration procedures. The company
was founded in March 2022 as an independent, publicly traded
spin-off of the Dental and Spine business units of Zimmer Biomet to
breathe new life, dedicated energy, and strategic focus to its
portfolio of trusted brands and products. From its headquarters in
Westminster, Colorado, and additional facilities around the globe,
the company serves customers in over 70 countries worldwide with a
robust offering of dental and spine solutions including
differentiated product platforms supported by extensive clinical
evidence. For more information about ZimVie, please visit us at
www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or
Instagram.
About Brainlab AGAt Brainlab, we digitize
medical workflows, from diagnosis to therapy, to offer clinicians
and patients better treatment possibilities. Our innovative digital
ecosystem forms the basis for modern healthcare technology in 6300
hospitals in 120 countries. At the forefront of health technology
for over 30 years, Munich-based Brainlab employs around 2200 people
with expertise across the entire healthcare value chain in 25
locations worldwide. For more information, please visit Brainlab
and follow on LinkedIn, Twitter, Facebook and Instagram.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements concerning
ZimVie’s expectations, plans, prospects, and product and service
offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs,
expectations, and assumptions of management and are subject to
significant risks, uncertainties, and changes in circumstances that
could cause actual outcomes and results to differ materially from
the forward-looking statements. For a list and description of some
of such risks and uncertainties, see ZimVie’s periodic reports
filed with the U.S. Securities and Exchange Commission (SEC). These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in ZimVie’s filings with the SEC. Forward-looking statements speak
only as of the date they are made, and ZimVie disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise. Readers of this press release are cautioned not to
rely on these forward-looking statements, since there can be no
assurance that these forward-looking statements will prove to be
accurate. This cautionary note is applicable to all forward-looking
statements contained in this press release.
Media Contact Information:
ZimVieLaura Driscoll •
Laura.Driscoll@ZimVie.com(774) 284-1606
ZimVie SpineMark Richards •
Mark.Richards@ZimVie.com(512) 913-9572
Brainlab AG | GlobalBernadette Erwig •
presse@brainlab.com
Investor Contact Information:
Gilmartin Group LLCMarissa Bych •
Marissa@gilmartinir.com
ZimVie (NASDAQ:ZIMV)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
ZimVie (NASDAQ:ZIMV)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024